Abraxis BioScience

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Abraxis BioScience
Industry Pharmaceutical
Founded 2001 (2001) in Los Angeles, California[1]
Founder Dr. Patrick Soon-Shiong
Defunct 2010
Headquarters Los Angeles, USA
Key people
Mr. Rick Click, Chief Information Officer and Global IT Officer; Dr. Nguyen V. Dat Ph.D., Vice President of Clinical Research
Products Protein-based therapeutics and technologies for treatment of cancer and other critical illnesses
Brands Abraxane
Services Cancer drugs
Owner Celgene

Abraxis BioScience was a global biopharmaceutical company that developed treatments for critically ill patients. It had over 2000 employees worldwide inb 2007.[2] Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology.[3] From this the company developed Abraxane, a treatment for metastatic breast cancer.[4]

In 2010, Abraxis BioScience was acquired by Celgene Corporation.[5]

History[edit]

Abraxis was incorporated in 2001 in Los Angeles.[1] Besides cancer treatments, it provided treatment for multiple sclerosis, Alzheimer's, and some cardiovascular diseases.[1] It had manufacturing plants in Melrose Park, Illinois and Phoenix, Arizona.[1]

In August 2007, Abraxis announced it would undergo a restructuring to separate it's "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research subunits to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., NASDAQABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., NASDAQAPPX).[6] This reorganization was completed in November 2007.[7] During the reorganization, the new Abraxis Bioscience was known briefly as New Abraxis.[7]

In 2010, Abraxis BioScience was acquired by Celgene Corporation.[8] Per Celgene's website, as of at least 2016 Abraxis no longer exists as a named division within Celgene.

References[edit]

  1. ^ a b c d "Company Overview of Abraxis BioScience, Inc.". Bloomberg. Retrieved October 17, 2016. 
  2. ^ BioPortfolio, 2007, "InDepth Summary", 10/11/2009[dead link]
  3. ^ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
  4. ^ Hoovers.[dead link]
  5. ^ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
  6. ^ Van Arnum, Patricia (1 August 2007). "Abraxis BioScience Plans to Separate into Two Companies". Pharmaceutical Technology. Retrieved 2015-08-07 – via Highbeam Research. 
  7. ^ a b Gopalakrishnan, Lisa (13 November 2007). FORM 8-K (Report). United States Securities and Exchange Commission. Retrieved 2015-08-07. 
  8. ^ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.

External links[edit]